The aim of this study was to develop diagnostic models comprising serological tumor markers and gadoxetate disodium-enhanced magnetic resonance imaging (EOB-MRI) features for patients with LR-M lesions by LI-RADS version 2018 (v2018). We retrospectively analyzed prospectively collected data from 45 consecutive at risk patients with LR-M observations and generated diagnostic models for LR-M to predict tumors with a cholangiocarcinoma component (M-CC). Among these models, carbohydrate antigen (CA) 19-9 alone demonstrated excellent diagnostic specificity, while the model integrating both CA 19-9 and the EOB-MRI feature “blood products in mass” achieved optimal overall performance.
This abstract and the presentation materials are available to members only; a login is required.